302 related articles for article (PubMed ID: 21701499)
21. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
[TBL] [Abstract][Full Text] [Related]
22. Drugs for rare disorders.
Cremers S; Aronson JK
Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
[TBL] [Abstract][Full Text] [Related]
23. Drugs Against Rare Diseases: Are The Regulatory Standards Higher?
Gobburu J; Pastoor D
Clin Pharmacol Ther; 2016 Oct; 100(4):322-3. PubMed ID: 27326701
[TBL] [Abstract][Full Text] [Related]
24. Accelerating orphan drug development.
Coté TR; Xu K; Pariser AR
Nat Rev Drug Discov; 2010 Dec; 9(12):901-2. PubMed ID: 21119719
[TBL] [Abstract][Full Text] [Related]
25. Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period.
Sarpatwari A; Beall RF; Abdurrob A; He M; Kesselheim AS
Health Aff (Millwood); 2018 May; 37(5):732-737. PubMed ID: 29733729
[TBL] [Abstract][Full Text] [Related]
26. Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval.
Harada K; Toriyabe K; Ono S
J Clin Pharmacol; 2020 Jan; 60(1):117-124. PubMed ID: 31364772
[TBL] [Abstract][Full Text] [Related]
27. History of Orphan Drug Regulation-United States and Beyond.
Haffner ME
Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514
[TBL] [Abstract][Full Text] [Related]
28. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
29. Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.
Pauwels K; Huys I; Casteels M; Larsson K; Voltz C; Penttila K; Morel T; Simoens S
Orphanet J Rare Dis; 2017 Feb; 12(1):36. PubMed ID: 28209180
[TBL] [Abstract][Full Text] [Related]
30. Do investors value the FDA orphan drug designation?
Miller KL
Orphanet J Rare Dis; 2017 Jun; 12(1):114. PubMed ID: 28629392
[TBL] [Abstract][Full Text] [Related]
31. The Food and Drug Administration's Office of Orphan Products Development: incentives, grants, and special designations speed therapies for orphan diseases.
Haffner ME
Retina; 2005 Dec; 25(8 Suppl):S89-S90. PubMed ID: 16374359
[No Abstract] [Full Text] [Related]
32. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
33. Translation of rare disease research into orphan drug development: disease matters.
Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
[TBL] [Abstract][Full Text] [Related]
34. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases.
Miller KL; Fermaglich LJ; Maynard J
Orphanet J Rare Dis; 2021 Jun; 16(1):265. PubMed ID: 34107994
[TBL] [Abstract][Full Text] [Related]
35. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
Pariser AR; Xu K; Milto J; Coté TR
Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
[TBL] [Abstract][Full Text] [Related]
36. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
Valverde AM; Reed SD; Schulman KA
Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
[TBL] [Abstract][Full Text] [Related]
37. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
38. Challenges in orphan drug development and regulatory policy in China.
Cheng A; Xie Z
Orphanet J Rare Dis; 2017 Jan; 12(1):13. PubMed ID: 28100254
[TBL] [Abstract][Full Text] [Related]
39. "Creating hope" and other incentives for drug development for children.
Connor E; Cure P
Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
[TBL] [Abstract][Full Text] [Related]
40. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
Mechler K; Mountford WK; Hoffmann GF; Ries M
Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]